Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by MoreUpThanDownon Apr 17, 2021 6:36am
306 Views
Post# 33016576

LEARNING HOW NEW STRATEGEY WORKS... FROM SZLS Q & A...

LEARNING HOW NEW STRATEGEY WORKS... FROM SZLS Q & A...First bit of info from Q & A............Q. How is this acquisition beneficial to StageZero Life Sciences? A. Cancer tests have to be administered by a healthcare provider, preferably a physician experienced in cancer care. StageZero has now partnered with an innovative, telehealth-based Oncology/early disease group with an established presence in all 50 US states. Patients and employers/organizations will now have access to leading oncologists, patented clinical protocols for the prevention and treatment of cancer, and StageZeros Next Generation Multi-Cancer Test Panel - Aristotle; all delivered via Telehealth. Care Oncology currently has thousands of patients they are currently working with. Additionally, employers have informed us that access to an organization such as Care Oncology is a necessary step to providing care for their employees who test positive on Aristotle. The acquisition also opens up multiple revenue streams beyond just the Aristotle test. ............... 2nd bit of info from Q & A......Q. Who is the AVRT program target market? A. The AVRT program will be targeting two specific groups: Consumers who want to live better, longer. This includes consumers who are concerned about developing cancer and other chronic diseases and those who believe they are at a higher risk of developing cancer. This particular program is not for current cancer patients. Employers who want to mitigate catastrophic health claims by keeping their employees healthy...... end of info from Q & A. So, I've now learned that AVRT, which includes Aristotle, will still be targeting employers and not just consumers. Also it states employers need access to care for employees who test positive for Aristotle, which SZLS indicates is why they need Care Oncology; but that means employers are talking to SZLS about Aristotle, so says the Q & A. Employers and consumers... I didn't clearly understand how the new strategy was set up when I asked about it in a former post. I've now found some answers directly from SZLS's Q & A. Thank you Mykndrsn for the suggestion to read the Q & A and the MD&A. Suggest anyone else unsure read it as well. Now to review the MD&A... All IMO. DYODD.
<< Previous
Bullboard Posts
Next >>